Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

Thrombospondin plays a vital role in the immune privilege of the eye. 2005.

Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):279-94. No abstract available.

PMID:
17613842
2.

Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. 2004.

Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, Dana MR.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):275-8. No abstract available.

PMID:
17613841
3.

Neural progenitor cells lack immunogenicity and resist destruction as allografts. 2003.

Hori J, Ng TF, Shatos M, Klassen H, Streilein JW, Young MJ.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):261-73. No abstract available.

PMID:
17613840
4.

Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. 2001.

Mo JS, Streilein JW.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):249-59. No abstract available.

PMID:
17613839
5.

Evidence for antigen-specific immune deviation in patients with acute retinal necrosis. 2001.

Kezuka T, Sakai JI, Usui N, Streilein JW, Usui M.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):241-8. No abstract available.

PMID:
17613838
6.

Immune privilege and immunogenicity reside among different layers of the mouse cornea. 2000.

Hori J, Joyce NC, Streilein JW.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):225-39. No abstract available.

PMID:
17613837
7.

Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells. 1997.

Taylor AW, Alard P, Yee DG, Streilein JW.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):215-24. No abstract available.

PMID:
17613836
8.

Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites. 1989.

Ksander BR, Streilein JW.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):205-13. No abstract available.

PMID:
17613835
9.

Two waves of virus following anterior chamber inoculation of HSV-1. 1987.

Atherton SS, Streilein JW.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):195-204. No abstract available.

PMID:
17613834
10.

Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. 1981.

Streilein JW, Niederkorn JY.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):187-94. No abstract available.

PMID:
17613833
11.

Immune response to immunization via the anterior chamber of the eye. II. An analysis of F1 lymphocyte-induced immune deviation. 1978.

Kaplan HJ, Streilein JW.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):179-85. No abstract available.

PMID:
17613832
12.

An analysis of graft-versus-host disease in Syrian hamsters. III. Hematological manifestations: description and studies in pathogenesis. 1972.

Streilein JW, Streilein J.

Ocul Immunol Inflamm. 2007 May-Jun;15(3):165-77. No abstract available.

PMID:
17613831
13.

Immunosuppressive properties of the pigmented epithelial cells and the subretinal space.

Zamiri P, Sugita S, Streilein JW.

Chem Immunol Allergy. 2007;92:86-93. Review.

PMID:
17264485
14.

B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.

Sugita S, Keino H, Futagami Y, Takase H, Mochizuki M, Stein-Streilein J, Streilein JW.

Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5376-84.

PMID:
17122127
15.

Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation.

Zamiri P, Masli S, Streilein JW, Taylor AW.

Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3912-8.

PMID:
16936104
16.

Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11405-10. Epub 2006 Jul 18.

17.

Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation.

Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE.

Cornea. 2006 May;25(4):443-7.

PMID:
16670483
18.

Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells.

Masli S, Turpie B, Streilein JW.

Int Immunol. 2006 May;18(5):689-99. Epub 2006 Mar 28.

PMID:
16569680
19.

CD8+ T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 immunity in eye-derived tolerance.

Keino H, Masli S, Sasaki S, Streilein JW, Stein-Streilein J.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1533-42.

PMID:
16565389
20.

Induction of eye-derived tolerance does not depend on naturally occurring CD4+CD25+ T regulatory cells.

Keino H, Takeuchi M, Kezuka T, Hattori T, Usui M, Taguchi O, Streilein JW, Stein-Streilein J.

Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1047-55.

PMID:
16505040
21.

B7+ iris pigment epithelium induce CD8+ T regulatory cells; both suppress CTLA-4+ T cells.

Sugita S, Ng TF, Lucas PJ, Gress RE, Streilein JW.

J Immunol. 2006 Jan 1;176(1):118-27. Erratum in: J Immunol. 2006 Feb 15;176(4):2670.

22.
23.

Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages.

Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW.

J Clin Invest. 2005 Sep;115(9):2363-72.

24.

Analysis of immune privilege in eyes with Mycobacteria tuberculosa adjuvant-induced uveitis.

Mo JS, Streilein JW.

Ocul Immunol Inflamm. 2005 Apr-Jun;13(2-3):139-47.

PMID:
16019673
25.
26.

Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling.

Cursiefen C, Ikeda S, Nishina PM, Smith RS, Ikeda A, Jackson D, Mo JS, Chen L, Dana MR, Pytowski B, Kruse FE, Streilein JW.

Am J Pathol. 2005 May;166(5):1367-77.

27.
28.

Thrombospondin plays a vital role in the immune privilege of the eye.

Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW.

Invest Ophthalmol Vis Sci. 2005 Mar;46(3):908-19.

PMID:
15728547
29.
30.

The MICA5.1 allele is not associated with susceptibility to effects of ultraviolet-B radiation on induction of contact hypersensitivity.

Niizeki H, Matsunaga T, Iwata T, Shimizu T, Kurimoto I, Naruse T, Inoko H, Streilein JW.

J Dermatol Sci. 2004 Sep;35(3):221-3. No abstract available.

PMID:
15381244
31.

Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.

Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW.

Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2666-73.

PMID:
15277490
32.

Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity.

Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, Dana MR.

Nat Med. 2004 Aug;10(8):813-5. Epub 2004 Jul 4.

PMID:
15235599
33.
34.

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW.

J Clin Invest. 2004 Apr;113(7):1040-50.

35.

Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis.

Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW.

Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1117-24.

PMID:
15037577
36.
37.

A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.

Arancibia-Cárcamo CV, Osawa H, Arnett HA, Háskova Z, George AJ, Ono SJ, Ting JP, Streilein JW.

Eur J Immunol. 2004 Feb;34(2):471-80.

38.

Vulnerability of allogeneic retinal pigment epithelium to immune T-cell-mediated damage in vivo and in vitro.

Zamiri P, Zhang Q, Streilein JW.

Invest Ophthalmol Vis Sci. 2004 Jan;45(1):177-84.

PMID:
14691171
39.

Ocular immune privilege: therapeutic opportunities from an experiment of nature.

Streilein JW.

Nat Rev Immunol. 2003 Nov;3(11):879-89. Review. No abstract available.

PMID:
14668804
40.

New thoughts on the immunology of corneal transplantation.

Streilein JW.

Eye (Lond). 2003 Nov;17(8):943-8.

PMID:
14631401
42.

Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation.

Streilein JW.

J Leukoc Biol. 2003 Aug;74(2):179-85. Review.

PMID:
12885934
44.

Neural progenitor cells lack immunogenicity and resist destruction as allografts.

Hori J, Ng TF, Shatos M, Klassen H, Streilein JW, Young MJ.

Stem Cells. 2003;21(4):405-16.

45.

Effect of local macrophage depletion on cellular immunity and tolerance evoked by corneal allografts.

Slegers TP, van der Gaag R, van Rooijen N, van Rij G, Streilein JW.

Curr Eye Res. 2003 Feb;26(2):73-9.

PMID:
12815525
46.

By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma.

Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze DV, Ksander BR, Streilein JW, John SW.

J Exp Med. 2003 May 19;197(10):1335-44.

47.

[Angiogenesis and lymphangiogenesis in the cornea. Pathogenesis, clinical implications and treatment options].

Cursiefen C, Seitz B, Dana MR, Streilein JW.

Ophthalmologe. 2003 Apr;100(4):292-9. German.

PMID:
12682761
48.

Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology.

Cursiefen C, Chen L, Dana MR, Streilein JW.

Cornea. 2003 Apr;22(3):273-81. Review.

PMID:
12658100
49.
50.

Chemokine gene expression in iris-ciliary body during experimental autoimmune uveoretinitis.

Ohta K, Yamagami S, Wiggert B, Dana MR, Streilein JW.

Curr Eye Res. 2002 Jun;24(6):451-7.

PMID:
12525972

Supplemental Content

Loading ...
Support Center